Small caps round-up: Imaginatik, Braveheart, Healthcare Locums...

Imaginatik has signed a new annual contract with a leading provider of healthcare services and medical research in the US. The contract has an initial start-up phase worth $0.12m in the current calendar year, followed by an ongoing annual contract worth $0.15m a year, with Imaginatik supplying its innovation software platform, Innovation Central, to achieve strategic operational objectives. The firm said this is "a strong validation of the increased value attributed to Imaginatik's enhanced full service innovation solutions." Shares gained 33.33% to 0.50p. Penny stock Braveheart Investment Group, has been appointed to manage a £50m growth loan fund aimed at supporting small to medium-sized enterprises in Northern Ireland. Braveheart is the lead bidder in a consortium of firms. The fund will operate on a matched funding basis and will be constructed as a limited partnership with a 10-year term, subject to extension. The regional business development agency has committed £25m to the fund, while a further £25m is being committed by the private sector. The company said the move is the direct result of its strategy to increase the fee earning side of the business. Shares gained 12.82% to 11.00p. Healthcare Locums, a medical staff provider, has told investors that proceedings have been filed against the firm Permian Master Fund; Permian Investments Partners; Arundel Capital; Arundel Long Fund; Arundel Hedge Fund; Privet Capital and Flinn Investments. They allege that HL and three of its former directors made misrepresentations during 2010 concerning the Company's profitability and its accounting practices. The firm is taking legal advice. Shares dropped 16.76% to 2.83p. Synchronica, a mobile phone messaging technology group, has launched a low-risk, "pay as you grow" solution for mobile operators. The service does not require a capital expenditure and is designed to help operators combat the threat from OTT players, such as Google and WhatsApp. The solution is based on technology from NewPace and follows last week's announcement of a partnership deal between the two companies for the development, sales and marketing of NewPace's RCS platform. Shares fell 5.41% to 13.12p. NR